| NHS |
cohort |
3 |
2 |
Nurses' Health Study |
| NIAAA |
cohort |
3 |
3 |
National Institute on Alcohol Abuse and Alcoholism |
| NIAAA/COGA Sharing Repository |
cohort |
2 |
1 |
Sharing Repository |
| nicotine |
drug |
154 |
112 |
(-)-nicotine hydrogen tartrate, (−)-nicotine hydrogen tartrate salt, IV nicotine, NIC, acute nicotine administration, acute nicotinic administration, any illicit drugs, alcohol, or nicotine, chronic nicotine, cigarettes, nicotine, nicotine dependence, nicotine dose, nicotine hydrogen tartrate salt, nicotine spray, plasma nicotine, prenatal nicotine exposure, regular use of nicotine, saliva nicotine, tobacco |
| nicotine addiction |
phenotype |
22 |
16 |
FTND score, addiction, addiction to nicotine, high nicotine addiction, nicotine addiction, nicotine addiction phenotype, nicotine dependence |
| nicotine dependence |
phenotype |
105 |
5 |
addiction, case–control status for nicotine dependence, cigarette-based ND, current nicotine dependence, dependence, dichotomous nicotine dependence phenotype, DSM‑IV ND, DSM-IV nicotine dependence, DSM nicotine dependence, Fagerström Nicotine Tolerance score, Fagerstrom score, Fagerstrom scores, Fagerstrom Test for Nicotine Dependence, Fagerström Test for Nicotine Dependence, FTND, FTND≤1, FTND≥4, FTND-defined nicotine dependence, FTND dependence on nicotine, heavy smoking, lifetime nicotine dependence symptoms, ND, ND-related behaviors, negative difference, nicotine, nicotine addiction, nicotine dependence, Nicotine Dependence, nicotine dependence etiology, nicotine dependence (HONC), nicotine dependence measures, nicotine dependence (mFTQ), nicotine dependence phenotype, nicotine dependence risk, nicotine dependence symptoms, nicotine dependent, nicotine dependent cases, nicotine dependent individuals, smoking, smoking behavior, Smoking Dependence, smoking phenotype, Tobacco dependence |
| nicotine use |
phenotype |
16 |
6 |
indicator of nicotine use, nicotine consumption, nicotine intake, nicotine self-administration, nicotine use, past-30-day nicotine use |
| nicotine withdrawal |
phenotype |
15 |
14 |
nicotine withdrawal, nicotine withdrawal behaviors, nicotine withdrawal symptoms, withdrawal, withdrawal symptoms |
| nicotinic acetylcholine receptor |
drug |
17 |
15 |
nAChR, nAChRs, neuronal nAChRs, nicotinic AChR, nicotinic acetylcholine receptor, nicotinic acetylcholine receptors, nicotinic receptors |
| NIDA |
cohort |
5 |
2 |
NIDA individuals, National Institute on Drug Abuse |
| NIDA/MNB |
cohort |
2 |
1 |
|
| NIH |
cohort |
4 |
2 |
National Institutes of Health |
| NIMH |
cohort |
5 |
2 |
National Institute of Mental Health, National Institute on Mental Health |
| nitric oxide |
drug |
6 |
3 |
NO |
| nitrocellulose membranes |
drug |
2 |
— |
|
| NKAIN2 |
gene |
2 |
2 |
Na+/K+ transporting ATPase interacting 2 |
| NK cells |
cohort |
4 |
1 |
|
| NKX2-1 |
gene |
4 |
4 |
NKX2-1, NKX2.1, NKX2–1, Nkx2-1, Nkx2.1, TTF-1 |
| NLAES |
cohort |
4 |
3 |
1992 NLAES, NLAES sample, National Longitudinal Alcohol Epidemiologic Survey, National Longitudinal Alcohol Epidemiological Survey |
| NLAES sample |
cohort |
2 |
1 |
NLAES |
